RxDoctor Payments Data

Kenneth Kato, MD

Ophthalmology · Tallahassee, FLNPI 1790780450

Payments from drug & device makers

$3,133in general payments, 2019–2025

Across 130 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$676
  • Amgen$610
  • Alcon$490
  • Aerie Pharmaceuticals, Inc.$328
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$255
  • Novartis$199
  • plus $576 from 9 others

What the payments were for

  • Food & beverage$3,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,133 in reported general payments places this provider in the 60th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$233,875
Medicare patients
674
Services billed
1,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost128$52,135
RestasisCyclosporine35$26,927
RhopressaNetarsudil Mesylate62$24,246
Latanoprost919$16,509
Alphagan PBrimonidine Tartrate35$13,094
Travoprost71$12,962
VyzultaLatanoprostene Bunod23$7,631
RocklatanNetarsudil Mesylat/Latanoprost23$7,377
Brimonidine Tartrate262$7,365
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$6,854
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat317$6,229
Prednisolone Acetate172$6,141
SimbrinzaBrinzolamide/Brimonidine Tart31$6,040
Dorzolamide Hcl212$3,836
Brinzolamide12$3,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$676$92,155198 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$328$31,62385 claims
Bausch & Lomb Americas Inc.Vyzulta$189$7,63123 claims
AlconSimbrinza$490$6,04031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →